Anti-IMP3 IGF2BP3 Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, ICC, IP, FC |
---|---|
Primary Accession | O00425 |
Host | Rabbit |
Isotype | Rabbit IgG |
Reactivity | Rat, Human, Mouse |
Clonality | Monoclonal |
Format | Liquid |
Description | Anti-IMP3 IGF2BP3 Monoclonal Antibody . Tested in WB, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat. |
Gene ID | 10643 |
---|---|
Other Names | Insulin-like growth factor 2 mRNA-binding protein 3, IGF2 mRNA-binding protein 3, IMP-3, IGF-II mRNA-binding protein 3, KH domain-containing protein overexpressed in cancer, hKOC, VICKZ family member 3, IGF2BP3, IMP3, KOC1, VICKZ3 |
Calculated MW | 63705 Da |
Application Details | WB 1:500-1:2000 ICC/IF 1:50-1:200 IP 1:50 FC 1:50 |
Contents | Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol, 0.4-0.5mg/ml BSA. |
Clone Names | Clone: AEDB-9 |
Immunogen | A synthesized peptide derived from human IMP3 RNA-binding protein that act as a regulator of mRNA translation and stability. Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. Binds to sequences in the 3'-UTR of CD44 mRNA. |
Purification | Affinity-chromatography |
Storage | Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles. |
Name | IGF2BP3 |
---|---|
Synonyms | IMP3, KOC1, VICKZ3 |
Function | RNA-binding factor that may recruit target transcripts to cytoplasmic protein-RNA complexes (mRNPs). This transcript 'caging' into mRNPs allows mRNA transport and transient storage. It also modulates the rate and location at which target transcripts encounter the translational apparatus and shields them from endonuclease attacks or microRNA-mediated degradation. Preferentially binds to N6- methyladenosine (m6A)-containing mRNAs and increases their stability (PubMed:29476152). Binds to the 3'-UTR of CD44 mRNA and stabilizes it, hence promotes cell adhesion and invadopodia formation in cancer cells. Binds to beta-actin/ACTB and MYC transcripts. Increases MYC mRNA stability by binding to the coding region instability determinant (CRD) and binding is enhanced by m6A-modification of the CRD (PubMed:29476152). Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. |
Cellular Location | Nucleus. Cytoplasm. Cytoplasm, P-body. Cytoplasm, Stress granule. Note=Found in lamellipodia of the leading edge, in the perinuclear region, and beneath the plasma membrane. The subcytoplasmic localization is cell specific and regulated by cell contact and growth. Localized at the connecting piece and the tail of the spermatozoa. Colocalized with CD44 mRNA in RNP granules. In response to cellular stress, such as oxidative stress, recruited to stress granules |
Tissue Location | Expressed in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of testis, growing oocytes, spermatogonia and semen (at protein level) Expressed in cervix adenocarcinoma, in testicular, pancreatic and renal-cell carcinomas (at protein level). Expressed ubiquitously during fetal development at 8 and 14 weeks of gestation. Expressed in ovary, testis, brain, placenta, pancreatic cancer tissues and pancreatic cancer cell lines. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.